Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 5 410 M
EBIT 2016 1 430 M
Net income 2016 414 M
Debt 2016 5 106 M
Yield 2016 0,57%
Sales 2017 5 653 M
EBIT 2017 1 527 M
Net income 2017 596 M
Debt 2017 4 319 M
Yield 2017 0,85%
P/E ratio 2016 66,81
P/E ratio 2017 25,59
EV / Sales2016 3,27x
EV / Sales2017 2,99x
Capitalization 12 587 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
08/24Ex-dividend day
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
08/24 PERRIGO COMPANY PLC : ex-dividend day
08/18 PERRIGO : Learn how to target a 20% return on Tesla Motors, or get option-trade ..
08/18 PERRIGO : Drug maker acquiring distributor
08/15 PERRIGO COMPANY PLC : Post Earnings Coverage as Perrigo Doubles Profit
08/15DJStada Arzneimittel Braced for Investor Battle
08/10 PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
08/10 SunPower and Perrigo skid while Disney and Yelp climb
08/10 S&P 500 MOVERS : Prgo, rl
08/10DJU.S. HOT STOCKS : Hot Stocks to Watch
08/10DJPERRIGO : Misses Expectations and Cuts Guidance
More news
Sector news : Pharmaceuticals - NEC
11:37aDJShares Fall as Health-Care Sector Loses Ground -- Update
08:49aDJPFIZER : to Buy Some Of Astra's Antibiotics -- WSJ
08/24DJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
08/24DJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 20
Average target price 109 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John T. Hendrickson President, Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Judy L. Brown Executive VP, Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Gerald K. Kunkle Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY12 587
JOHNSON & JOHNSON15.57%324 776
ROCHE HOLDING LTD.-11.47%217 694
NOVARTIS AG-9.45%213 882
PFIZER INC.7.87%211 206
MERCK & CO., INC.18.76%173 462
More Results